Fact Meets Function

Glycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro.

Researchers investigated whether glycyl-L-histidyl-L-lysine (GHK), a tripeptide, could prevent protein aggregation and cell death caused by excess copper and zinc in cultured central nervous system cells (in vitro study). The study found that GHK demonstrated protective effects against both copper- and zinc-induced protein aggregation and cellular toxicity in these cell culture models. This is in vitro evidence and does not establish clinical efficacy in human subjects.

Glycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro. Read Post »

Rigid-flexible nanocarriers loaded with active peptides for antioxidant and anti-inflammatory applications in skin.

Researchers developed hybrid nanocarriers combining rigid and flexible components to deliver active peptides, including GHK-Cu, for potential antioxidant and anti-inflammatory effects in skin applications. The nanocarriers were evaluated in vitro for their ability to reduce oxidative stress and inflammatory markers in skin cell models. This is an in vitro study, representing early-stage research on nanoparticle formulation and delivery mechanisms.

Rigid-flexible nanocarriers loaded with active peptides for antioxidant and anti-inflammatory applications in skin. Read Post »

Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration.

Researchers investigated NAD concentration as a biomarker for personalizing nicotinamide mononucleotide (NMN) supplementation in humans. The study examined whether baseline NAD levels could predict individual responses to NMN treatment, potentially allowing tailored dosing strategies. This is human clinical evidence exploring the biological basis for individualized supplement approaches.

Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration. Read Post »

Role and Potential Mechanisms of Nicotinamide Mononucleotide in Aging.

This review article examined the role of nicotinamide mononucleotide (NMN) in aging processes and explored potential biological mechanisms through which NMN may influence age-related changes (Review). The authors synthesized evidence suggesting NMN acts as a NAD+ precursor that may affect cellular energy metabolism, mitochondrial function, sirtuins, and DNA repair pathways implicated in aging.

Role and Potential Mechanisms of Nicotinamide Mononucleotide in Aging. Read Post »

β-Nicotinamide mononucleotide supplementation prolongs the lifespan of prematurely aged mice and protects colon function in ageing mice.

This animal model study investigated β-nicotinamide mononucleotide (NMN) supplementation in mice with premature aging and age-related decline. Researchers found that NMN supplementation extended lifespan in prematurely aged mice and improved colon function in aging mice, suggesting potential effects on age-related physiological decline. This is **animal model evidence** and does not directly translate to human outcomes without further clinical investigation.

β-Nicotinamide mononucleotide supplementation prolongs the lifespan of prematurely aged mice and protects colon function in ageing mice. Read Post »

A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment.

This preclinical study evaluated a nanoparticle delivery platform designed to promote mucosal healing and modulate immune responses in inflammatory bowel disease models. The research demonstrated that the nanoparticle formulation containing KPV (a tripeptide) enhanced intestinal barrier function and reduced inflammatory markers in laboratory and animal model systems. This represents early-stage evidence (animal model/in vitro) requiring further human clinical testing before any therapeutic application can be established.

A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. Read Post »

A Synthetic ERR Agonist Alleviates Metabolic Syndrome.

Researchers investigated the effects of SLU-PP-332, a synthetic estrogen-related receptor (ERR) agonist, on metabolic syndrome in an animal model. The compound was found to alleviate metabolic syndrome symptoms, suggesting potential therapeutic applications for this drug target. This is animal model evidence and requires further human clinical investigation before applicability to patient care.

A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Read Post »

Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats.

This study examined the effects of Dihexa, an angiotensin IV analog, on rat models of Huntington’s disease induced by 3-nitropropionic acid exposure. Researchers found that Dihexa treatment reduced motor deficits and protected against neuronal damage in treated animals compared to controls. **Evidence level: Animal model** (Note: The source designation of “Human Clinical” appears inconsistent with the study design, which used rat models rather than human subjects).

Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats. Read Post »

Toxicology study profile of Nicotinamide mononucleotide after acute and 90-day sub chronic dosing in Wistar rats and mutagenicity tests.

This in vitro and animal model study evaluated the safety profile of nicotinamide mononucleotide (NMN) through acute and 90-day sub-chronic dosing experiments in Wistar rats, along with mutagenicity testing. The research assessed toxicological endpoints including clinical signs, body weight changes, organ weights, blood chemistry, and genetic damage potential to establish safety parameters for NMN exposure. This evidence comes from animal model studies and in vitro mutagenicity assays, which represent preliminary safety data that typically precedes human clinical evaluation.

Toxicology study profile of Nicotinamide mononucleotide after acute and 90-day sub chronic dosing in Wistar rats and mutagenicity tests. Read Post »

Scroll to Top